Stage, screen and film actress Delta Burke is leading the BYETTA Let’s Talk campaign, sponsored by Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY).
Sanofi-aventis announced that a new disposable insulin pen, SoloSTAR? for use with the 24-hour insulin LANTUS? or/and the rapid-acting insulin APIDRA? will be available in Europe starting April 2007.
World diabetes leaders left the Global Changing Diabetes Leadership Forum, which took place in New York City on 13?14 March 2007, with a sense of activism to return home to start changing diabetes.
Novo Nordisk announced that the European Commission has approved Levemir? (insulin detemir) for once-daily use in combination with oral antidiabetic drugs (OADs).
Joslin researchers discover a surprising culprit in the search for causes of diabetic birth defects. protein makes it possible for high blood glucose to enter embryonic cells.
Researchers found a 69 percent increase in the rate of the disease in Ontario between 1995 and 2005 — far beyond the 60 percent global predicted increase for 2030 and above rates projected for Canada by then, reported by Reuters Canada.
A new study from Joslin Diabetes Center may shed light on why some people can eat excessive amounts of food and not gain weight or develop type 2 diabetes, while others are more likely to develop obesity and this most common form of diabetes on any diet.
A new finding, from the Asia-Pacific Cohort Studies Collaboration (APCSC) and published in the AsiaPacific Journal of Clinical Nutrition, shows that up to 12 percent of cardiovascular deaths in the region (heartdisease and stroke) are due to diabetes.
Novartis announced that it has received an “approvable letter” from the US Food and Drug Administration (FDA) for Galvus? (vildagliptin), under review for US approval as a new once-daily oral treatment for patients with type 2 diabetes.
Using a $2.5 million, three-year grant from the Juvenile Diabetes Research Foundation (JDRF), Emory transplant researchers plan to develop pig islets as an alternative to human islets for transplant into patients with Type 1 diabetes. If their research is successful, clinical trials of the porcine islet transplants into humans could begin within the next three years.